EU regulators okay Qlaira for the treatment of heavy menstrual bleeding
Bayer Schering Pharma AG, Germany, has successfully concluded the European registration procedure for the introduction of Qlaira in the new indication treatment of heavy menstrual bleeding in women without organic pathology who desire oral contraception. The Netherlands served as Reference Member State for the decentralized procedure to gain Europe-wide Marketing Authorization for the new indication. Qlaira is the first in a new class of oral contraceptives to deliver estradiol, the same estrogen as the one produced by the female body. In addition, it also contains dienogest, a progestogen which is well-investigated. It has a unique dosing regimen which has been designed to deliver hormones at the right levels at the right time during the cycle. Qlaira is already marketed in over 25 European countries as an oral contraceptive.
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.